Table 1 Included CDR Assessments
Drug | Indication |
|---|---|
Simeprevir (Galexos) | Hepatitis C, chronic |
Onabotulinumtoxin A (Botox) | Migraine, chronic |
Rotigotine (Neupro) | Parkinson disease |
Eplerenone (Inspra) | Reduce risk of heart failure |
Aclidinium bromide (Tudorza Genuair) | Chronic obstructive pulmonary disease |
Tocilizumab (Actemra) | Polyarticular juvenile idiopathic arthritis |
Golimumab (Simponi) | Ulcerative colitis |
Ingenol mebutate (Picato) | Keratosis, actinic |
Somatropin (Genotropin) | Growth hormone deficiency, adult |
Ocriplasmin (Jetrea) | Vitreomacular adhesion |
Lurasidone (Latuda) | Schizophrenia |
Ulipristal acetate (Fibristal) | Uterine fibroids |
Azilsartan medoxomil (Edarbi) | Hypertension |
Azilsartan medoxomil + chlorthalidone (Edarbyclor) | Hypertension |
Perampanel (Fycompa) | Epilepsy, partial-onset seizures |
Everolimus (Afinitor) | Angiomyolipoma associated with tuberous sclerosis complex |
Zolpidem tartrate (Sublinox) | Insomnia, short-term treatment |
Dimethyl fumarate (Tecfidera) | Multiple sclerosis, relapsing |
Nebivolol (Bystolic) | Hypertension |
Adalimumab (Humira) | Juvenile idiopathic arthritis |
Abatacept (Orencia) | Rheumatoid arthritis |
Eculizumab (Soliris) | Atypical hemolytic uremic syndrome |
Palonosetron hydrochloride (Aloxi) | Chemotherapy induced nausea |
Glycopyrronium (Seebri) | Chronic obstructive pulmonary disease |
Elvitegravir + cobicistat + emtricitabine + tenofovir disoproxil fumarate (Stribild) | HIV-1 infection |
Pirfenidone (Esbriet) | Pulmonary fibrosis |
Collagenase clostridium histolyticum (Xiaflex) | Dupuytren’s contracture |
Ivacaftor (Kalydeco) | Cystic fibrosis (G551D mutation) |
Apixaban (Eliquis) | Thromboembolic event prevention (atrial fibrillation) |
Fidaxomicin (Dificid) | Clostridium difficile infection |